Swiss drug developer Windward Bio Group targets a $1 billion valuation in its US IPO, raising $185.3 million for antibody medicines treating respiratory and dermatologic diseases. The offering is back
reuters · 2026-11-09 04:09
Swiss biotech firm Windward Bio filed for a US IPO on Nasdaq to fund its pipeline of long-lasting antibody treatments for asthma and inflammatory diseases. The company secured up to $365 million from
reuters · 2026-10-23 13:51
Novo Holdings, the investment arm of Novo Nordisk, has resumed full capital allocations targeting US renewables and AI infrastructure, citing improved valuation and market stability despite ongoing ta
bloomberg · 2026-08-12 11:00
Novo Holdings, controlling obesity drugmaker Novo Nordisk, invested 500 million euros in the pan-European Scaleup Europe Fund. The fund targets technology companies in digital, physical, and health se
reuters · 2026-06-04 06:01